Want to join the conversation?
$AGN and $HUM will initially focus on improving health of patients with central nervous system conditions, including Alzheimer's disease, as well as glaucoma and other eye diseases with opportunities to expand into other therapeutic areas as collaboration progresses. It will also focus on patient/caregiver relationship and interventional research.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.